A1 Refereed original research article in a scientific journal

Influence of repeated plaque visualization on cardiovascular risk reduction after 3 years : a randomized controlled trial




AuthorsWhitmore, Kristyn; Zhou, Zhen; Ryan, Jacqueline D. M.; Magnussen, Costan G.; Carrington, Melinda J.; Marwick, Thomas H.; CAUGHT CAD investigators

PublisherOXFORD UNIV PRESS

Publishing placeOXFORD

Publication year2025

JournalEuropean Journal of Preventive Cardiology

Journal name in sourceEUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY

Journal acronymEUR J PREV CARDIOL

Volume32

Issue7

First page 596

Last page605

Number of pages10

ISSN2047-4873

eISSN2047-4881

DOIhttps://doi.org/10.1093/eurjpc/zwae026

Web address https://doi.org/10.1093/eurjpc/zwae026

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/484866472


Abstract

Aims

Helping people to understand their cardiovascular (CV) risk can influence the choices they make for risk reduction, including medication adherence and lifestyle modification. This study sought whether repeated visualization of coronary artery calcium (CAC) images was effective in sustaining long-term risk control in primary prevention, independent of a risk reduction programme.

Methods and results

Asymptomatic, statin-na & iuml;ve participants, 40-70 years, with a family history of premature coronary artery disease and a CAC score from 1-400 were randomized to a nurse-led CV risk reduction programme or standard care with bi-annual reviews. Only the intervention group (220 of 449 participants) visualized their CAC image (with repeat exposure in the first 3 months) and were initiated on statin therapy. The primary outcome was change in Framingham Risk Score (FRS) at 36 months, and the impact of CAC image recall on CV risk was assessed. The reduction in FRS (difference in differences (DID) -3.4% [95% CI: -4.4% to -2.4%], P <= 0.001 and low density lipoprotein cholesterol -1.2 mmol/L [95% CI: -1.4 to -1.0], P <= 0.001) over 36 months was greater in the intervention than the control group. Within the intervention group, sustained recall of CAC images at 24 months was associated with lower systolic blood pressure (DID -4.3 mmHg [95% CI: -7.7 to -0.9], P = 0.01) and waist circumference (DID -2.0 cm [95% CI: -3.9 to -0.1], P = 0.03) at 36 months compared to unsustained recall.

Conclusion

A nurse-led programme, combining personalized patient visualization of CAC imaging with statin therapy, is beneficial for improving CV risk. Recalling the presentation of CAC images through repeated visual exposure may influence risk reduction.

Registration

Australia New Zealand Clinical Trials Registry: ACTRN12614001294640

Lay summary

  • ​​​​​​​This trial sought to determine whether visualization of coronary artery calcium (CAC) images influences behaviour change and cardiovascular risk reduction within a structured nurse-led programme vs. standard care.
  • Intervention participants visualized their personalized CAC images within the first three months and commenced statin therapy. Control participants were blinded to their CAC images and were not provided statin therapy. Intervention participants had a greater absolute reduction in the Framingham Risk Score (difference in differences -3.4% [95% CI: -4.4% to -2.4%], P <= 0.001) compared to controls.
  • Those with sustained recollection of their CAC images within the intervention group also had greater reductions in systolic blood pressure and waist circumference.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
The CAUGHT-CAD study is funded by a project grant from the National Health and Medical Research Council, Canberra, Australia (1080582). M.J.C. receives an endowed fellowship in the Cardiology Centre of Excellence from Filippo and Maria Casella. T.H.M. is supported by an investigator grant (2008129) from the National Health and Medical Research Council, Canberra, Australia.


Last updated on 2025-23-06 at 12:21